scholarly journals Efficacy and Safety of Remdesivir over Two Waves of the SARS-CoV-2 Pandemic

Antibiotics ◽  
2021 ◽  
Vol 10 (12) ◽  
pp. 1477
Author(s):  
Mariacristina Poliseno ◽  
Crescenzio Gallo ◽  
Donatella Concetta Cibelli ◽  
Graziano Antonio Minafra ◽  
Irene Francesca Bottalico ◽  
...  
Keyword(s):  
Antiviral Treatment ◽  
High Rate ◽  
Efficacy And Safety ◽  
Invasive Ventilation ◽  
Non Invasive ◽  
Clinical Recovery ◽  
Non Invasive Ventilation ◽  
Group A ◽  
Group B ◽  
Low Rate

The aim of this study is to describe the features, the outcomes, and the clinical issues related to Remdesivir administration of a cohort of 220 patients (pts) with COVID-19 hospitalized throughout the last two pandemic waves in Italy. One hundred and nine pts were enrolled from 1 September 2020, to 28 February 2021 (Group A) and 111 from 1 March to 30 September 2021 (Group B). Notably, no differences were reported between the two groups neither in the timing of hospitalization. nor in the timing of Remdesivir administration from symptoms onset. Remarkably, a higher proportion of pts with severe COVID-19 was observed in Group B (25% vs. 10%, p < 0.001). At univariate and multivariate analysis, rather than the timing of Remdesivir administration, age, presence of coexisting conditions, D-dimers, and O2 flow at admission correlated positively to progression to non-invasive ventilation, especially for patients in Group B. However, the rate of admission in the Intensive Care Unit and/or death was comparable in the two groups (7% vs. 4%). Negligible variations in serum GOT, GPT, GGT, and eGFR levels were detected. A mean reduction in heart rate was noticed within the first three days of antiviral treatment (p < 0.001). Low rate of ICU admission, high rate of clinical recovery, and good drug safety were observed in COVID-19 patients treated with Remdesivir during two diverse pandemic waves.

scholarly journals Predictors of Non-invasive Ventilation Response Do Not Indicate Response to High Flow Nasal Oxygen: A Bicentric Observational Study.

2021 ◽  
Author(s):  
Alexander Hermann ◽  
Lena-Franziska Lauschke-Leberfinger ◽  
Johann Auer ◽  
Irene Steiner ◽  
Robin Ristl ◽  
...  
Keyword(s):  
Heart Rate ◽  
Sofa Score ◽  
Base Excess ◽  
High Flow ◽  
Invasive Ventilation ◽  
Non Invasive ◽  
Non Invasive Ventilation ◽  
Rate Base ◽  
Group A ◽  
Group B

Abstract BackgroundIn patients receiving high flow nasal oxygen (HFNO), predicting chance of response is crucial in order to avoid unnecessary delay of intubation. Whether commonly used predictors of non-invasive ventilation (NIV) response may be as applicable for HFNO, is unclear.MethodsWe conducted a retrospective bi-centric analysis of adults treated with HFNO in two Austrian medical intensive care units from 01/2014 until 09/2017. Predictive value of respiratory rate, PaO2, PaCO2, SpO2, ROX index, pH, heart rate, base excess, SOFA-Score and SAPS III was analysed by means of logistic regression with HFNO responding as dependent variable. Calculations were also done separately in patients receiving HFNO as post-extubation support (Group A) and all other indications (Group B). ResultsWe registered 127 patients (m:f = 70:57, median age: 67 [IQR 53-77] years). Forty-eight patients (37.8%) received HFNO as post-extubation support and were assigned to group A. Seventy-nine patients (62.2%) received HFNO due to any other indication and were assigned to group B. Criteria of HFNO response were fulfilled by 42 patients (87.5%) of group A and 53 (67.1%) of group B patients.Whereas respiratory rate, PaO2, PaCO2, SpO2, pH, heart rate, base excess, SOFA-Score and SAPS III did not differ between responders and non-responders, ROX index showed significant association with HFNO success in all patients. With increasing ROX index, the odds for response increased (OR [95% CI]: baseline: 1.21 [1.05, 1.38], p = 0.0069, after 2 hours: 1.19 [1.05; 1.34], p = 0.0061, after 6 hours: 1.23 [1.06; 1.42], p = 0.0049). Subgroup analyses revealed similar odds ratios for ROX index (baseline: group A: 1.17 [0.90; 1.52], p = 0.24; group B: 1.22 [1.04; 1.43], p = 0.015; after 2 hours: 1.30 [0.94; 1.82], p = 0.12, group B: 1.18 [1.03; 1.34], p = 0.014; after 6 hours: 1.76 [1.01; 3.06], p = 0.047, group B: 1.19 [1.03; 1.37], p = 0.022). ConclusionsCriteria of HFNO success deviate from criteria for response to NIV. ROX index indicated HFNO response in a wide range of indications.

scholarly journals Remdesivir in Severe COVID-19 and Non-Invasive Ventilation: A Real-Life Experience

Healthcare ◽  
2021 ◽  
Vol 9 (9) ◽  
pp. 1108
Author(s):  
Francesca Simioli ◽  
Carmine Nicoletta ◽  
Maria Rosaria Valentino ◽  
Maria Martino ◽  
Anna Annunziata ◽  
...  
Keyword(s):  
Clinical Improvement ◽  
Antiviral Treatment ◽  
Clinical Signs ◽  
Real Life ◽  
Lung Damage ◽  
Lung Involvement ◽  
Invasive Ventilation ◽  
Non Invasive ◽  
Markers Of Inflammation ◽  
Non Invasive Ventilation

Background: Antiviral treatment is a hot topic regarding therapy for COVID-19. Several antiviral drugs have been tested in the months since the pandemic began. Yet only Remdesivir obtained approval after first trials. The best time to administer Remdesivir is still a matter for discussion and this could also depend upon the severity of lung damage and the staging of the infection. Methods: We performed a real-life study of patients hospitalized forCOVID-19 and receiving non-invasive ventilation (NIV). In this single-center study, a 5 day course of Remdesivir was administered as compassionate use. Further therapeutic supports included antibiotics, low molecular weight heparin and steroids. Data collection included clinical signs and symptoms, gas exchange, laboratory markers of inflammation, and radiological findings. Major outcomes were de-escalation of oxygen-support requirements, clinical improvement defined by weaning from ventilation to oxygen therapy or discharge, and mortality. Adverse drug reactions were also recorded. All data were collected during hospitalization and during a 20-day follow up after treatment. Results: 51 patients were enrolled. A global clinical improvement was recorded in 22 patients (43%) at 12 days, and 36 (71%) at 20 days; in particular, at 12 days, 27 patients (53%) also had a de-escalation of oxygen-support class from a therapeutic point of view. Remdesivir use was associated with a lower hazard ratio for clinical improvement in the elderly (older than 70 years) and in subjects with more extensive lung involvement (total severity score at HRCT of more than 14). The 20-day mortality was 13%. Conclusions: Results demonstrated that Remdesivir is associated with an improvement in clinical, laboratory and radiological parameters in patients with severe COVID-19 and showed an overall mortality of 13%. We conclude that, in this cohort, Remdesivir was a beneficial add-on therapy for severe COVID-19, especially in adults with moderate lung involvement at HRCT.

scholarly journals Puerperal Group A Streptococcal sepsis: a case report

2021 ◽  
Vol 10 (12) ◽  
pp. 4573
Author(s):  
Nithya J. ◽  
Sathyamurthy G. ◽  
Balavinoth R.
Keyword(s):  
Maternal Mortality ◽  
Clinical Signs ◽  
Vaginal Swab ◽  
Invasive Infection ◽  
Invasive Ventilation ◽  
Non Invasive ◽  
Prompt Treatment ◽  
Non Invasive Ventilation ◽  
Life Threatening ◽  
Group A

Group A Streptococcal (GAS) sepsis in puerperium is one of the recognised causes of maternal mortality. Though the onset is often insidious, it can progress rapidly to a life-threatening invasive infection, toxin-mediated shock, and end-organ failure, even before clinical signs become apparent. We report a case of puerperal GAS sepsis that was successfully managed. 24-years-old para 1 was readmitted to the intensive care unit requiring non-invasive ventilation on postnatal day 6 with clinical and biochemical features of sepsis. Blood culture, episiotomy wound swab, and high vaginal swab grew GAS. Broad-spectrum antibiotics initiated. She developed ascites that progressively increased and needed therapeutic paracentesis. She was discharged after four weeks of hospitalization. Early identification and prompt treatment are the keys to prevent severe morbidity and maternal mortality.

Efficacy and Safety of Oral Ivermectin and Topical Permethrin in the Treatment of Scabies

2020 ◽  
Vol 33 (1) ◽  
pp. 41-47
Author(s):  
Mohsena Akhter ◽  
Ishrat Bhuiyan ◽  
Zulfiqer Hossain Khan ◽  
Mahfuza Akhter ◽  
Gulam Kazem Ali Ahmad ◽  
...  
Keyword(s):  
Skin Diseases ◽  
Close Contact ◽  
Randomized Study ◽  
Sarcoptes Scabiei ◽  
Efficacy And Safety ◽  
Common Skin ◽  
Group A ◽  
The Mean ◽  
The Difference ◽  
Group B

Background: Scabies is one of the most common skin diseases in our country. It is caused by the mite Sarcoptes scabiei var hominis, which is an ecto-parasite infesting the epidermis. Scabies is highly contagious. Prevalence is high in congested or densely populated areas. Individuals with close contact with an affected person should be treated with scabicidal which is available in both oral and topical formulations. The only oral but highly effective scabicidal known to date is Ivermectin. Amongst topical preparations, Permethrin 5 % cream is the treatment of choice. Objective: To evaluate the efficacy & safety of oral Ivermectin compared to topical Permethrin in the treatment of scabies. Methodology: This prospective, non-randomized study was conducted at the out-patient department of Dermatology and Venereology of Shaheed Suhrawardy Medical College & Hospital over a period of 6 months, from August 2016 to January 2017. The study population consisted of one hundred patients having scabies, enrolled according to inclusion criteria. They were divided into two groups. group A was subjected to oral Ivermectin and the group B to Permethrin 5% cream. Patients were followed up on day 7 and 14 for assessment of efficacy and safety. Result: The mean scoring with SD in group A (Ivermectin) and group B (Permethrin) were 8.26 ± 2.22 and 7.59 ± 2.01 respectively at the time of observation. The difference between the mean score of the two group is not significant (p=0.117) the mean scoring with SD in group A and group B were 4.54 ± 2.05 and 1.64 ± 1.84 respectively at 7thdays. The difference between the mean score of the two group is significant (p<0.001). The mean scoring with SD in group A and group B were 2.68± 2.35 and .36± 1.10 respectively at 14th day difference between the mean score of the group is significant (p<0.001). Conclusion: Topical application of permethrin 5% cream is more effective and safer than oral Ivermectin in the treatment of scabies. TAJ 2020; 33(1): 41-47

Non-invasive ventilation in palliative care: a systematic review

2020 ◽  
Vol 110 (6) ◽  
Author(s):  
Teresa Diaz de Teran ◽  
Elena Barbagelata ◽  
Catia Cilloniz ◽  
Antonello Nicolini ◽  
Tommaso Perazzo ◽  
...  
Keyword(s):  
Systematic Review ◽  
Palliative Care ◽  
Invasive Ventilation ◽  
Non Invasive ◽  
Non Invasive Ventilation
Sign in / Sign up

Export Citation Format

Share Document